Interpace (IDXG) Director Vijay Aggarwal Receives RSU Award

What Happened Vijay Aggarwal, a director of Interpace Biosciences, Inc. (IDXG), was granted 69,252 restricted stock units (RSUs) on August 20, 2026. The RSUs were recorded at $0.00 per unit (no cash paid) and are reported as a derivative award (transaction code A). Each RSU represents a contingent right to the economic equivalent of one share of common stock.

Key Details

• Transaction date: 2026-08-20; reported on Form 4 filed the same day (timely filing).
• Award: 69,252 RSUs @ $0.00 (derivative grant).
• Vesting: RSUs vest in four equal annual installments beginning August 20, 2027, subject to the reporting person’s continued service on each vesting date (footnotes F1, F2).
• Shares owned after transaction: Not disclosed in the provided filing.
• Transaction type: Grant/award (A); not a purchase or sale, and no immediate marketable shares were issued.

Context RSU grants are typically compensation for service. These RSUs do not represent immediately tradable shares — they convert to or pay the economic equivalent of shares only as they vest per the stated schedule. Because this was an award (not a purchase or sale), it does not directly signal buying or selling intent by the insider.